From this it appears that combining cancer metabolism therapy with immunotherapy will be a prospective strategy for overcoming cancer [117], and in particularly, mIDH inhibitors should be paired with the immune checkpoint inhibitors to improve the clinical response of patients with IDH-mutated tumors [118]. This evidence concerns the gene IDH1 and cancer.